Limitations and Confusing Aspects of Diagnostic Testing for Neurologic Lyme Disease in the United States-Reference-Cited by-同舟云学术

Limitations and Confusing Aspects of Diagnostic Testing for Neurologic Lyme Disease in the United States

Published:2019-01 Issue:1 Volume:57 Page:
ISSN:0095-1137
Container-title:Journal of Clinical Microbiology
language:en
Short-container-title:J Clin Microbiol

Author:

Theel Elitza S.¹,Aguero-Rosenfeld Maria E.²,Pritt Bobbi¹,Adem Patricia V.³,Wormser Gary P.⁴

Affiliation:

1. Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA

2. Department of Pathology, New York University, New York, New York, USA

3. Department of Pathology, New York Medical College, Valhalla, New York, USA

4. Division of Infectious Diseases, New York Medical College, Valhalla, New York, USA

Abstract

In the United States, laboratories frequently offer multiple different assays for testing of cerebrospinal fluid (CSF) samples to provide laboratory support for the diagnosis of central nervous system Lyme disease (CNSLD). Often included among these diagnostic tests are the same enzyme immunoassays and immunoblots that are routinely used to detect the presence of antibodies to Borrelia burgdorferi in serum.

Funder

Mayo Clinic

Publisher

American Society for Microbiology

Subject

Microbiology (medical)

Link

https://journals.asm.org/doi/pdf/10.1128/JCM.01406-18

Reference34 articles.

1. Lyme Disease Testing by Large Commercial Laboratories in the United States

2. Neurologic Manifestations of Lyme Disease

3. EFNS guidelines on the diagnosis and management of European Lyme neuroborreliosis